Markets:

Overview

News

Currencies

International

Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

53.45 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday ↗

September 30, 2024

Via Benzinga

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO ↗

September 26, 2024

The company is working on a drug that mimics apelin, which is released following exercise.

Via Investor's Business Daily

Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

September 24, 2024

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

Via MarketBeat

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

September 17, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Peering Into Structure Therapeutics's Recent Short Interest ↗

July 15, 2024

Via Benzinga

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

August 27, 2024

Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

August 26, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024 ↗

August 09, 2024

GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

August 08, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Make Your Summer Unforgettable ↗

July 30, 2024

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Via InvestorPlace

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon. ↗

July 22, 2024

Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.

Via The Motley Fool

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 17, 2024

Via Benzinga

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? ↗

July 17, 2024

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Via Benzinga

ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 17, 2024

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in July 2024 ↗

July 12, 2024

There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment.

Via InvestorPlace

Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug

July 09, 2024

Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been

Via MarketBeat

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

July 03, 2024

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Via MarketBeat

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

July 02, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy

Via MarketBeat

The 3 Smartest Biotech Stocks to Buy With $5K Right Now ↗

June 28, 2024

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.

Via InvestorPlace

Could Structure Therapeutics Become the Next Novo Nordisk? ↗

June 17, 2024

Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.

Via The Motley Fool

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar ↗

June 14, 2024

The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.

Via Investor's Business Daily

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? ↗

June 11, 2024

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.

Via The Motley Fool

Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗

June 10, 2024

The company is focusing on obesity treatment after its glaucoma drug failed.

Via Investor's Business Daily

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? ↗

June 09, 2024

Structure Therapeutics has a long way to go before beating Wegovy.

Via The Motley Fool

Top Names Performance Update - Saturday, June 8 ↗

June 08, 2024

I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone...

Via Talk Markets

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.